Clinical trials
Phase 2 Leukemia, Myelomonocytic, Chronic trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
11 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2012 | 1 |
| 2016 | 1 |
| 2019 | 1 |
| 2021 | 2 |
| 2023 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 6 |
| Active, not recruiting | 1 |
| Enrolling by invitation | 1 |
| Recruiting | 1 |
| Unknown status | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Groupe Francophone des Myelodysplasies | 2 |
| Cogent Biosciences, Inc. | 1 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| Institut Paoli-Calmettes | 1 |
| Janssen Research & Development, LLC | 1 |
| Merck Sharp & Dohme LLC | 1 |
| Millennium Pharmaceuticals, Inc. | 1 |
| Novartis Pharmaceuticals | 1 |
| Taiho Oncology, Inc. | 1 |
| Vion Pharmaceuticals | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Myelomonocytic, Chronic | 11 |
| Myelodysplastic Syndromes | 8 |
| Leukemia, Myeloid, Acute | 7 |
| Myeloproliferative Disorders | 4 |
| Congenital Abnormalities | 3 |
| Leukemia | 3 |
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 3 |
| Blast Crisis | 2 |
| Burkitt Lymphoma | 2 |
| Hodgkin Disease | 2 |
Trials
Showing 1 to 11 of 11. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.